VENTRIPOINT DIAGNOSTICS LTD

VentriPoint Diagnostics turns heart‑disease imaging into 3‑D models—but its negative PE ratio and steep stock decline raise urgent investor concerns.

Ventripoint Diagnostics raises shares to pay debenture interest, preserving liquidity but diluting shareholders—what this means for investors and future growth.

VentriPoint Diagnostics: a promising heart‑disease tech firm now battling declining stock, a negative P/E, and modest market cap—can it turn innovation into profit?

Discover how VentriPoint Diagnostics transforms heart disease diagnosis with 3‑D imaging tech, boosting accuracy and shaping the future of cardiac care.

VentriPoint Diagnostics transforms existing imaging into 3‑D heart models, boosting diagnostic accuracy and patient outcomes—discover how this Calgary‑based firm is reshaping heart disease care.

Ventripoint Diagnostics partners with UniDoc to launch a remote cardiac screening platform, promising scalable, cloud‑based heart care and potential growth for investors.

Discover how Calgary‑based VentriPoint Diagnostics is revolutionizing heart disease detection with 3‑D imaging tech and AI‑powered models—boosting accuracy and early care.

VentriPoint Diagnostics: Calgary‑based company using 3‑D imaging tech to boost heart disease diagnostics, expanding market reach amid R&D challenges.

VentriPoint Diagnostics: Calgary‑based company using existing imaging tech to create 3‑D heart models, boosting heart disease diagnosis accuracy and treatment planning.

VentriPoint Diagnostics: 3D heart‑disease tech meets a steeply falling stock, negative P/E and market doubts. Can innovation rescue its future?